 |
|
|
| |
5-Year Outcomes of Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial Treatment of HIV-1 in Adults With High Baseline HIV-1 RNA and/or Low CD4 Count in Two Phase 3 Randomized Clinical Trials
|
| |
| |
IDWeek 2022, 19-23 Oct, Washington, DC
Moti Ramgopal,1 Anson Wurapa,2 Axel Baumgarten,3 Mezgebe Berhe,4 Anton Pozniak,5 Chloe Orkin,6 Juan Manuel Tiraboschi,7 Debbie Hagins,8 Hailin Huang,9 Kristen Andreatta,9 Nathan Unger,9 Jason Hindman,9 Hal Martin,9 Jared Baeten,9 Olayemi Osiyemi10
1Midway Research Center and Midway Specialty Care Center, Fort Pierce, FL; 2Infectious Disease Specialists of Atlanta, Decatur, GA; 3Zentrum für Infektiologie, Berlin, Germany; 4North Texas Infectious Diseases Consultants, Dallas, TX; 5Chelsea and Westminster Hospital, London, UK;
6Queen Mary University of London; 7Hospital Universitari de Bellvitge, Barcelona, Spain; 8Coastal CARE Centers, Savannah, GA; 9Gilead Sciences, Inc., Foster City, CA; 10Triple O Research Institute PA., West Palm Beach, FL
|
| |
|
|
|
|
|
